Clinical Trials Logo
  1. Home
  2. Newly Diagnosed Multiple Myeloma
  3. NCT05088330

A Study to Access of Daratumumab Combined With VRD in the Treatment of Patients With Standard-risk Newly Diagnosed MM

Newly Diagnosed Multiple Myeloma Clinical Trial

Official title:
A Prospective Study of Daratumumab Combined With VRD in the Treatment of Patients With Newly Diagnosed Standard-risk Multiple Myeloma : a Single-center, Single-arm Clinical Study

Clinical Trial Summary

This is an open-label, single arm study to access the effect of treatment with D-VRD in patients with newly diagnosed standard risk multiple myeloma.

Clinical Trial Description

Research object:Newly diagnosed standard-risk multiple myeloma (NDMM) diagnosed according to the International Myeloma Working Group (IMWG) standards and who have been assessed to receive Autologous Stem Cell Transplantation (ASCT) but actively refused.Objective: To explore the therapeutic options of daratumamab (D) combined with bortezomib (V), lenalidomide (R) and dexamethasone ( d) for objective assessment of patients who can receive ASCT but not to receive transplantation.Main indicators:negative rate of minimal residual disease (MRD) upon completion of cycle 8 (24 weeks). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05088330
Study type Interventional
Source The First Affiliated Hospital of Soochow University
Contact
Status Not yet recruiting
Phase N/A
Start date December 1, 2021
Completion date December 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04052880 - Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM Phase 2
Active, not recruiting NCT03742297 - Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years Phase 3
Not yet recruiting NCT05558319 - NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide Phase 3
Recruiting NCT04891809 - Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM Phase 2
Not yet recruiting NCT05561049 - Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma
Completed NCT01936532 - Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06) Phase 2
Recruiting NCT05259553 - Biomarkers in Multiple Myeloma N/A
Completed NCT01809717 - Multiple Myeloma and Exercise N/A
Withdrawn NCT04348006 - Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients Phase 4
Terminated NCT03733691 - Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients Phase 2
Active, not recruiting NCT00405756 - A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. Phase 3
Recruiting NCT05665140 - Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients Phase 2/Phase 3
Active, not recruiting NCT03948035 - Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM Phase 3
Not yet recruiting NCT06348147 - Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation Phase 2
Recruiting NCT06324266 - Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation Phase 2/Phase 3